143 related articles for article (PubMed ID: 31336412)
1. Eskata (40% Hydrogen Peroxide Solution) for the Treatment of Seborrheic Keratoses.
Keaney T
J Drugs Dermatol; 2019 Jul; 18(7):s172. PubMed ID: 31336412
[TBL] [Abstract][Full Text] [Related]
2. Clinical Experience With 40% Hydrogen Peroxide Topical Solution for the Treatment of Seborrheic Keratosis.
Peredo M; Murphy E; Karibayeva D
J Drugs Dermatol; 2019 Jul; 18(7):s173-177. PubMed ID: 31336413
[TBL] [Abstract][Full Text] [Related]
3. Anatomic Site-Specific Treatment Response With 40% Hydrogen Peroxide (w/w) Topical Formulation for Raised Seborrheic Keratoses: Pooled Analysis of Data from Two Phase 3 Studies.
Smith SR; Xu S; Estes E; Shanler SD
J Drugs Dermatol; 2018 Oct; 17(10):1092-1098. PubMed ID: 30365590
[TBL] [Abstract][Full Text] [Related]
4. Hydrogen Peroxide 40% for the Treatment of Seborrheic Keratoses.
Funkhouser CH; Coerdt KM; Haidari W; Cardis MA
Ann Pharmacother; 2021 Feb; 55(2):216-221. PubMed ID: 32646224
[TBL] [Abstract][Full Text] [Related]
5. Enhancing Outcomes in Seborrheic Keratosis: Using a Novel Treatment Solution.
Schlesinger TE; Favre C
J Drugs Dermatol; 2019 Jul; 18(7):s178-182. PubMed ID: 31336414
[TBL] [Abstract][Full Text] [Related]
6. Hydrogen Peroxide Topical Solution, 40% (w/w) for the Treatment of Seborrheic Keratoses: A Review.
Murphy EC; Friedman AJ
Skin Therapy Lett; 2020 Jan; 25(1):1-4. PubMed ID: 32023021
[TBL] [Abstract][Full Text] [Related]
7. Assessing Patients' Satisfaction With Hydrogen Peroxide Topical Solution, 40% for Treatment of Raised Seborrheic Keratoses.
DuBois J; Grande K; Rhodes T; Schnyder J; Shanler SD
J Drugs Dermatol; 2020 Dec; 19(12):1184-1191. PubMed ID: 33346520
[TBL] [Abstract][Full Text] [Related]
8. Hydrogen peroxide 40% (Eskata) for seborrheic keratoses.
Med Lett Drugs Ther; 2018 Sep; 60(1556):157-158. PubMed ID: 30383728
[No Abstract] [Full Text] [Related]
9. Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302).
Baumann LS; Blauvelt A; Draelos ZD; Kempers SE; Lupo MP; Schlessinger J; Smith SR; Wilson DC; Bradshaw M; Estes E; Shanler SD
J Am Acad Dermatol; 2018 Nov; 79(5):869-877. PubMed ID: 29864467
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of topical treatments for seborrheic keratoses: a systematic review.
Natarelli N; Krenitsky A; Hennessy K; Moore S; Grichnik J
J Dermatolog Treat; 2023 Dec; 34(1):2133532. PubMed ID: 36215682
[TBL] [Abstract][Full Text] [Related]
11. Hydrogen Peroxide 40% (Eskata) for Seborrheic Keratosis.
Robertson S; Franko J
Am Fam Physician; 2019 Nov; 100(10):643-644. PubMed ID: 31730314
[No Abstract] [Full Text] [Related]
12. Eskata® (Hydrogen Peroxide 40%)-A Treatment for Seborrheic Keratosis.
Gupta AK; Versteeg SG; Abramovits W; Patel S; Vincent KD
Skinmed; 2019; 17(4):268-270. PubMed ID: 31627790
[No Abstract] [Full Text] [Related]
13. A-101, a Proprietary Topical Formulation of High-Concentration Hydrogen Peroxide Solution: A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Dose-Response Profile in Subjects With Seborrheic Keratosis of the Face.
DuBois JC; Jarratt M; Beger BB; Bradshaw M; Powala CV; Shanler SD
Dermatol Surg; 2018 Mar; 44(3):330-340. PubMed ID: 28902028
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and morphological effects of hydrogen peroxide 40% topical solution for the treatment of seborrheic keratoses, evaluated by dynamic optical coherence tomography.
Forouzandeh M; Rajabi-Estarabadi A; Williams NM; Avanaki MRN; Nouri K
Skin Res Technol; 2020 Jan; 26(1):142-145. PubMed ID: 31338893
[No Abstract] [Full Text] [Related]
15. Utility of 30% hydrogen peroxide in the treatment of seborrheic keratosis.
Suvarna P; Kayarkatte MN
Int J Dermatol; 2022 Sep; 61(9):1113-1116. PubMed ID: 35094378
[TBL] [Abstract][Full Text] [Related]
16. Unusual clinical manifestation of seborrheic keratosis on the scalp successfully treated with topical trichloroacetic acid: an atypical case report.
Komalasari DN; Djawad K; Nurdin AR; Paturusi II
Pan Afr Med J; 2020; 37():98. PubMed ID: 33425131
[TBL] [Abstract][Full Text] [Related]
17. A novel topical agent in the treatment of seborrheic keratoses: A proof of concept study by clinical and dermoscopic evaluation.
Lacarrubba F; Nasca MR; Verzì AE; Micali G
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28796288
[TBL] [Abstract][Full Text] [Related]
18. Managing Seborrheic Keratosis: Evolving Strategies and Optimal Therapeutic Outcomes.
Kao S; Kiss A; Efimova T; Friedman AJ
J Drugs Dermatol; 2018 Sep; 17(9):933-940. PubMed ID: 30235378
[TBL] [Abstract][Full Text] [Related]
19. Use of a keratolytic agent with occlusion for topical treatment of hyperkeratotic seborrheic keratoses.
Burkhart CG; Burkhart CN
Skinmed; 2008; 7(1):15-8. PubMed ID: 18174808
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and safety of 30% hydrogen peroxide with 50% trichloroacetic acid in seborrheic keratosis: a randomized controlled study.
Agrawal D; Adil M; Amin SS; Mohtashim M; Bansal R; Tabassum H
Ital J Dermatol Venerol; 2021 Aug; 156(4):489-495. PubMed ID: 32348081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
